🇺🇸 FDA
Patent

US 10077444

Compositions and methods for inhibiting expression of the LECT2 gene

granted A61PA61P1/16A61P13/12

Quick answer

US patent 10077444 (Compositions and methods for inhibiting expression of the LECT2 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
71
CPC classes
A61P, A61P1/16, A61P13/12